04:33 AM EDT, 09/16/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from its NIAGARA phase III trial showed IMFINZI in combination with chemotherapy has a statistically significant and clinically meaningful improvement in event-free survival and overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.

Patients treated with the IMFINZI perioperative regimen had a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm, according to the study.

About 67.8% of patients treated with the IMFINZI regimen were event-free at two years compared with 59.8% in the comparator arm, the company said.

The analysis also showed that the IMFINZI perioperative regimen reduced the risk of death by 25% versus neoadjuvant chemotherapy with radical cystectomy and about 82.2% of patients treated with the IMFINZI regimen were alive at two years compared to 75.2% in the comparator arm.

The company further said that IMFINZI is also being tested across early- and late-stage bladder cancer in various treatment combinations.

Price: 78.15, Change: -0.12, Percent Change: -0.15